These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 22090177)
1. Intramural delivery of bortezomib inhibits restenosis following arterial injury. Gong X; Zhou Y Vasa; 2011 Nov; 40(6):449-52. PubMed ID: 22090177 [TBL] [Abstract][Full Text] [Related]
2. The proteasome as a target for prevention of restenosis following vascular injury. Ayub B; Mangalmurti S; Matsumura ME Vasa; 2011 Nov; 40(6):425-6. PubMed ID: 22191123 [No Abstract] [Full Text] [Related]
3. Local administration of NF-kappa B decoy oligonucleotides to prevent restenosis after balloon angioplasty: an experimental study in New Zealand white rabbits. Kalinowski M; Viehofer K; Hamann C; Barry JJ; Kleb B; Klose KJ; Wagner HJ; Alfke H Cardiovasc Intervent Radiol; 2005; 28(3):331-7. PubMed ID: 15886949 [TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. Park JW; Qi WN; Cai Y; Urbaniak JR; Chen LE Plast Reconstr Surg; 2007 Dec; 120(7):1808-1818. PubMed ID: 18090742 [TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats. Chen FT; Liu YC; Yang CM; Yang CH Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3682-94. PubMed ID: 22538426 [TBL] [Abstract][Full Text] [Related]
6. [The inhibitive effect of sodium tanshinone II A sulfonic acid on intimal hyperplasia in rabbit iliac artery ballon injury model]. Chen YC; Chen HS; Long B; Liang YJ; Zeng Z Zhong Yao Cai; 2007 Jul; 30(7):811-5. PubMed ID: 17944192 [TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
8. [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells]. Lu SF; Lu H; Shen WY; Zhang JF; Liu P; Wang YR; Wang LX; Yang H; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1006-9. PubMed ID: 18928584 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Lövborg H; Oberg F; Rickardson L; Gullbo J; Nygren P; Larsson R Int J Cancer; 2006 Mar; 118(6):1577-80. PubMed ID: 16206267 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515 [TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822 [TBL] [Abstract][Full Text] [Related]
14. The effects of amiloride, a Na+-H+ exchange inhibitor, on iliac artery stenosis after balloon injury in rabbits. Fang XY; Lin NY; Li YG Biochem Cell Biol; 2010 Aug; 88(4):665-70. PubMed ID: 20651838 [TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1. Bosman MC; Schuringa JJ; Quax WJ; Vellenga E Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210 [TBL] [Abstract][Full Text] [Related]
17. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991 [TBL] [Abstract][Full Text] [Related]
18. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286 [TBL] [Abstract][Full Text] [Related]
19. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Zhang L; Zhang ZG; Liu X; Hozeska A; Stagliano N; Riordan W; Lu M; Chopp M Thromb Haemost; 2006 Jan; 95(1):166-73. PubMed ID: 16543976 [TBL] [Abstract][Full Text] [Related]
20. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]